Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Prostate Cancer

  Free Subscription

Articles published in Invest Radiol

Retrieve available abstracts of 5 articles:
HTML format
Text format

Single Articles

    September 2017
  1. PEREZ-LOPEZ R, Nava Rodrigues D, Figueiredo I, Mateo J, et al
    Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features.
    Invest Radiol. 2017 Sep 12. doi: 10.1097/RLI.0000000000000415.
    PubMed     Text format     Abstract available

    March 2017
  2. SMEENGE M, Tranquart F, Mannaerts CK, de Reijke TM, et al
    First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study.
    Invest Radiol. 2017 Mar 2. doi: 10.1097/RLI.0000000000000362.
    PubMed     Text format     Abstract available

    February 2017
  3. LEMBERSKIY G, Rosenkrantz AB, Veraart J, Taneja SS, et al
    Time-Dependent Diffusion in Prostate Cancer.
    Invest Radiol. 2017 Feb 9. doi: 10.1097/RLI.0000000000000356.
    PubMed     Text format     Abstract available

    May 2016
  4. OTHMAN AE, Falkner F, Weiss J, Kruck S, et al
    Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
    Invest Radiol. 2016;51:290-6.
    PubMed     Text format     Abstract available

    April 2015
  5. PANAGIOTAKI E, Chan RW, Dikaios N, Ahmed HU, et al
    Microstructural characterization of normal and malignant human prostate tissue with vascular, extracellular, and restricted diffusion for cytometry in tumours magnetic resonance imaging.
    Invest Radiol. 2015;50:218-27.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.